|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123950 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-04 13:19:46 |
|
注册时间: Date of Registration: |
2026-05-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
瑞植定制种植修复方案:前牙美学区即刻种植中的应用效果研究 |
|
Public title: |
Effect of BioRes Customized Implant Restoration on Immediate Implantation in the Anterior Aesthetic Zone: A Clinical Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
瑞植定制种植修复方案:前牙美学区即刻种植中的应用效果研究 |
|
Scientific title: |
Effect of BioRes Customized Implant Restoration on Immediate Implantation in the Anterior Aesthetic Zone: A Clinical Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郭泽鸿 |
研究负责人: |
郭泽鸿 |
|
Applicant: |
Guo Zehong |
Study leader: |
Guo Zehong |
|
申请注册联系人电话: Applicant telephone: |
+86 13728098343 |
研究负责人电话:
Study leader's |
+86 13728098343 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
36648547@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
36648547@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省广州市海珠区江南大道南366号 |
研究负责人通讯地址: |
中国广东省广州市海珠区江南大道南366号 |
|
Applicant address: |
366 Jiangnan Avenue South, Haizhu District, Guangzhou, Guangdong, China |
Study leader's address: |
366 Jiangnan Avenue South, Haizhu District, Guangzhou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南方医科大学口腔医院 |
||
|
Applicant's institution: |
Stomatological Hospital of Southern Medical University |
||
|
研究负责人所在单位: |
南方医科大学口腔医院 |
||
|
Affiliation of the Leader: |
Stomatological Hospital of Southern Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
NYKQ-EC-[2025] 26 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南方医科大学口腔医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Stomatological Hospital of Southern Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-08 00:00:00 | ||
|
伦理委员会联系人: |
麦宇芸 |
||
|
Contact Name of the ethic committee: |
Mai Yuyun |
||
|
伦理委员会联系地址: |
中国广东省广州市海珠区江南大道南366号 |
||
|
Contact Address of the ethic committee: |
366 Jiangnan Avenue South, Haizhu District, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 84406334 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
maiyuyun@foxmail.com |
|
研究实施负责(组长)单位: |
南方医科大学口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Stomatological Hospital of Southern Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广东省广州市海珠区江南大道南366号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
366 Jiangnan Avenue South, Haizhu District, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
|
研究疾病: |
前牙美学区即刻种植修复 |
||||||||||||||||||||||
|
Target disease: |
Immediate implant restoration in the aesthetic area of the anterior teeth |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本研究旨在通过开展一项开放性、前瞻性、单队列、单中心研究,全面评估BioRes瑞植定制种植修复方案在上颌前牙美学区行即刻种植治疗效果的安全性和有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to conduct an open, prospective, single-cohort, single-center study to comprehensively evaluate the safety and efficacy of the BioRes customized implant restoration program in immediate implant treatment in the aesthetic area of the maxillary anterior teeth. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 自愿配合该研究并签署研究知情同意书; 2. 性别不限,18岁<=年龄<=60岁,医从性良好; 3. 无法保留的患牙位于上颌前牙美学区:即13/-23/,且为单颗患牙; 4. 系统健康患者(美国麻醉医师协会- ASAⅠ、Ⅱ级:除外科疾病外,有轻度并发症,功能代偿健全); 5. 全口情况未罹患牙周病或牙周状况处于牙周维护期(菌斑指数< 20 %,探诊出血评分< 10 %),无牙龈退缩; 6. 根据术前CBCT评估,即使术中存在潜在的骨开窗,应仅限于牙槽的根尖1/3。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Voluntarily cooperate with this research and sign the informed consent form for the research; 2. Gender is not limited. Age range: 18 years old to 60 years old. Good medical compliance. 3. The affected tooth that cannot be retained is located in the aesthetic zone of the maxillary anterior teeth: that is, 13/-23/, and it is a single affected tooth. 4. Systemically healthy patients (American Society of Anesthesiologists - ASA Class I and II: With mild complications other than surgical diseases and sound functional compensation); 5. The entire mouth does not have periodontal disease or the periodontal condition is in the periodontal maintenance stage (plaque index < 20%, probing bleeding score < 10%), and there is no gingival recession. 6. According to the preoperative CBCT assessment, even if there is a potential bone fenestration during the operation, it should be limited to the apical one-third of the alveolar cavity. |
||||||||||||||||||||||
|
排除标准: |
1. 同时参与其他临床研究; 2. 患有常规种植手术禁忌证或无法控制的全身系统性疾病,包括: (1) 严重的全身性疾病: 1) 患有高血压,且收缩压(高压)>150mmHg 或舒张压(低压)>90mmHg 。 2) 患有未控制的糖尿病:空腹血糖>=7.0mmol/L或糖化血红蛋白(HbA1c>7%) 3) 患有心脏疾病(心功能3-4级),或出现端坐呼吸,下肢水肿等症状。 4) 患有心肺疾病,心衰患者。 5) 患有心脑血管疾病(半年内出现心绞痛,心肌梗死,脑梗,心绞痛近期频繁发作)。 6) 患有三度或二度Ⅱ型房室传导阻滞,双束支阻滞,阿斯综合征 7) 患有心脏瓣膜疾病。 8) 急性肝炎(会导致肝脏严重受损)。 9) 严重哮喘,严重咽炎,重度抑郁症。 10) 严重甲亢:脉搏>100次/分钟,基础代谢率>20%。 11) 血液疾病:血友病、白血病及其他出血性疾病,或因服用抗凝药物导致凝血障碍的患者,INR>3或凝血七项存在有临床意义的异常值。 (2) 长期服用以下药物: 1) 注射及大量口服双膦酸盐用于预防骨转移及治疗骨质疏松的患者。 2) 因使用激素类药物导致关节坏死的患者(典型案例:非典的患者)。 3) 长期肾上腺皮质激素治疗的患者; (3) 艾滋病、梅毒及吸毒患者。 (4) 因其余全身系统性疾病导致患者身体无法耐受手术者; (5) 牙龈及周围硬组织存在病理性改变者; 3. 伴有急性或严重的感染,白细胞计数>10^9/L者; 4. 拟采取种植区域存在不正常咬合关系或不良咬合习惯,可能造成种植体周围软组织创伤性吸收而导致手术失败;口腔黏膜病变;缺牙区有严重软组织炎性病变;张口受限; 5. 拔牙窝为I类:唇侧软组织完整,但拔牙后颊板部分缺失;或III类:拔牙后唇侧软硬组织均明显减少。 6. 药物过敏史:对术中及术后需使用的麻醉药品、消炎止痛药等多种药物存在严重过敏症状; 7. 处于妊娠期、月经期或哺乳期的女性; 8. 患有未经控制的牙周病或不良口腔卫生习惯无法改善者(探诊深度>4mm,BOP>10%); 9. 严重吸烟者(>10支/天); 10. 患有其余经评估后可能影响影响伤口愈合的系统性疾病患者,如慢性结核、甲减、自身免疫病等; 11. 恶性肿瘤病史,近5年恶性肿瘤放疗或化疗史; 12. 研究者认为因其他原因不适宜参加本次临床试验者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Participate in other clinical research simultaneously; 2. Patients with contraindications for conventional dental implant surgery or uncontrolled systemic diseases, including: (1) Severe systemic diseases: 1) Hypertension with systolic blood pressure (high pressure) > 150mmHg or diastolic blood pressure (low pressure) > 90mmHg. 2) Uncontrolled diabetes: fasting blood glucose >= 7.0mmol/L or glycated hemoglobin (HbA1c) > 7%. 3) Heart disease (cardiac function grade 3-4), or symptoms such as orthopnea and lower extremity edema. 4) Heart and lung diseases, heart failure patients. 5) Cardiovascular and cerebrovascular diseases (angina pectoris, myocardial infarction, cerebral infarction within half a year, or frequent recent angina pectoris attacks). 6) Third-degree or second-degree type II atrioventricular block, bifascicular block, Adams-Stokes syndrome. 7) Heart valve disease. 8) Acute hepatitis (causing severe liver damage). 9) Severe asthma, severe pharyngitis, severe depression. 10) Severe hyperthyroidism: pulse > 100 beats per minute, basal metabolic rate > 20%. 11) Blood diseases: hemophilia, leukemia and other bleeding disorders, or patients with coagulation disorders due to anticoagulant drugs, INR > 3 or clinically significant abnormal values in the seven coagulation tests. (2) Long-term use of the following drugs: 1) Patients who have received injections and large oral doses of bisphosphonates for the prevention of bone metastasis and treatment of osteoporosis. 2) Patients with joint necrosis due to the use of hormone drugs (typical case: SARS patients). 3) Patients treated with long-term adrenal cortical hormones. (3) AIDS, syphilis and drug addicts. (4) Patients whose bodies cannot tolerate surgery due to other systemic diseases. (5) Patients with pathological changes in the gums and surrounding hard tissues. 3. Those with acute or severe infections and a white blood cell count greater than 10^9/L; 4. Abnormal occlusal relationships or bad occlusal habits exist in the proposed implantation area, which may cause traumatic absorption of the soft tissues around the implant and lead to surgical failure. Oral mucosal lesions There is severe soft tissue inflammatory lesion in the area of missing teeth. Limited mouth opening; 5. The tooth socket is classified as type I: the labial soft tissue is intact, but the buccal plate is partially missing after tooth extraction; or type III: both the labial soft and hard tissues are significantly reduced after tooth extraction. 6. History of drug allergy: Severe allergic reactions to various drugs that will be used during and after the operation, including anesthetic drugs, anti-inflammatory and analgesic drugs, etc. 7. Women who are pregnant, menstruating or breastfeeding; 8. Those with uncontrolled periodontal disease or poor oral hygiene habits that cannot be improved (probing depth > 4mm, BOP > 10%); 9. Severe smokers (more than 10 cigarettes per day); 10. Patients with other systemic diseases that may affect wound healing after assessment, such as chronic tuberculosis, hypothyroidism, autoimmune diseases, etc. 11. History of malignant tumors, with a history of radiotherapy or chemotherapy for malignant tumors in the past 5 years; 12. Those who the researcher deems unsuitable to participate in this clinical trial for other reasons. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-01 00:00:00至 To 2029-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2029-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |